Monday, 14 September 2026European Markets
ExploreSearch
ViaNews EU

EU Tech Regulation

2 articles

Anthropic sues Pentagon over supply chain ban as AI labs face military-commercial split

Anthropic sues Pentagon over supply chain ban as AI labs face military-commercial split

Anthropic filed suit against the US Department of Defense on March 9 over designation as a supply chain security risk, marking the first legal challenge by a major AI lab to national security restrictions. The lawsuit comes as Google agrees to provide AI agents to the Pentagon and OpenAI's hardware chief resigns following a defense contract, signaling a strategic divide in how AI companies handle government work.

ViaNews Editorial Team (Europe)•
EU Caught Between Open AI Access and US-China Tech Race as Governance Models Diverge

EU Caught Between Open AI Access and US-China Tech Race as Governance Models Diverge

Europe faces a strategic dilemma as AI governance fractures along geopolitical lines, with the Pentagon banning Anthropic's Claude and India joining US supply chains. French AI leader Arthur Mensch argues the real battle is open versus closed AI systems, not geography—a debate with direct implications for Europe's AI Act and competitive positioning.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,285 source documents archived
Query this data → isubstrate.com